Risk of Hypovolemia Associated with Sodium-glucose Cotransporter-2 Inhibitors Treatment: A Meta-analysis of Randomized Controlled Trials

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Dec 1

PMID 36451919

Authors

Xi Rong

Yawen Zhu

Bo Wen

Kai Liu

Xinran Li

Qiling Gou

Xiaoping Chen

Affiliations

Soon will be listed here.

Abstract

Aim Of The Review: To assess the risk of hypovolemia for sodium-glucose cotransporter-2 (SGLT2) inhibitors treatment.

Method: A systematic literature retrieval was performed in PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and Scopus from inception up to 4 October 2022, Data for study characteristics and outcomes of interest were extracted from each eligible study. Risk ratios (RRs) with a 95% confidence interval (CI) for hypovolemia were calculated using a random-effect model.

Results: A total of 57 studies ( = 68,622) were included in our meta-analysis, with a result of 1,972 hypovolemia incidents (1,142 in the SGLT2 inhibitors group and 830 in the control group). The pooled RR was 1.12 (95% CI: 1.02-1.22). It is evident that receiving SGLT2 inhibitors increased the risk of hypovolemia. When stratified by category of SGLT2 inhibitors the result was consistent; when the subgroup was analyzed by age, the pooled RR was 1.07 (95% CI: 0.94-1.23) in patients aged ≥65 years and 1.14 (95% CI: 1.02-1.28) in those aged <65 years. When comparing the baseline estimated glomerular filtration rate (eGFR) of less than or equal to 60 mL/min/1.73 m with a baseline eGFR greater than 60 mL/min/1.73 m, the pooled RR was 1.21, (95% CI: 1.00-1.46) and 1.08, (95%CI: 0.98-1.20), respectively.

Conclusion: Our meta-analysis has demonstrated that SGLT2 inhibitors increased the risk of hypovolemia in patients with Type 2 Diabetes Mellitus (T2DM). It is necessary to pay attention to the risk of hypovolemia associated with SGLT2 inhibitors, especially in older individuals and those with moderate renal impairment.

Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/], identifier [CRD42020156254].

Citing Articles

Pros and Cons of Inpatient SGLT2i Use for Hyperglycemia and Heart Failure.

Fried H, Harris Y, Schulman-Rosenbaum R J Endocr Soc. 2025; 9(2):bvae229.

PMID: 39816910 PMC: 11733499. DOI: 10.1210/jendso/bvae229.

SGLT2 Inhibitors in Kidney Diseases-A Narrative Review.

Gajewska A, Wasiak J, Sapeda N, Mlynarska E, Rysz J, Franczyk B Int J Mol Sci. 2024; 25(9).

PMID: 38732178 PMC: 11084583. DOI: 10.3390/ijms25094959.

The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.

Bica I, Stoica R, Salmen T, Janez A, Volcansek S, Popovic D Medicina (Kaunas). 2023; 59(6).

PMID: 37374340 PMC: 10301940. DOI: 10.3390/medicina59061136.

Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure.

Nakagaito M, Imamura T, Ushijima R, Nakamura M, Kinugawa K Biomedicines. 2023; 11(3).

PMID: 36979855 PMC: 10046005. DOI: 10.3390/biomedicines11030876.

References

Bode B, Stenlof K, Sullivan D, Fung A, Usiskin K . Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013; 41(2):72-84. DOI: 10.3810/hp.2013.04.1020. View

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

Lee M, Brooksbank K, Wetherall K, Mangion K, Roditi G, Campbell R . Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation. 2020; 143(6):516-525. PMC: 7864599. DOI: 10.1161/CIRCULATIONAHA.120.052186. View

Weber M, Mansfield T, Alessi F, Iqbal N, Parikh S, Ptaszynska A . Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. Blood Press. 2015; 25(2):93-103. DOI: 10.3109/08037051.2015.1116258. View

Kohan D, Fioretto P, Tang W, List J . Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2013; 85(4):962-71. PMC: 3973038. DOI: 10.1038/ki.2013.356. View

Solomon S, McMurray J, Claggett B, de Boer R, DeMets D, Hernandez A . Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022; 387(12):1089-1098. DOI: 10.1056/NEJMoa2206286. View

Seino Y, Sasaki T, Fukatsu A, Sakai S, Samukawa Y . Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr Med Res Opin. 2014; 30(7):1219-30. DOI: 10.1185/03007995.2014.901943. View

Mudaliar S, Polidori D, Zambrowicz B, Henry R . Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside. Diabetes Care. 2015; 38(12):2344-53. DOI: 10.2337/dc15-0642. View

Bailey C, Morales Villegas E, Woo V, Tang W, Ptaszynska A, List J . Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med. 2014; 32(4):531-41. DOI: 10.1111/dme.12624. View

10.

Stenlof K, Cefalu W, Kim K, Alba M, Usiskin K, Tong C . Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15(4):372-82. PMC: 3593184. DOI: 10.1111/dom.12054. View

11.

Pearson E . Type 2 diabetes: a multifaceted disease. Diabetologia. 2019; 62(7):1107-1112. PMC: 6560016. DOI: 10.1007/s00125-019-4909-y. View

12.

Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S . Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015; 38(3):365-72. DOI: 10.2337/dc14-0666. View

13.

Ji L, Han P, Liu Y, Yang G, Dieu Van N, Vijapurkar U . Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes Obes Metab. 2014; 17(1):23-31. DOI: 10.1111/dom.12385. View

14.

Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde A, Sjostrom C . Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2013; 16(2):159-69. DOI: 10.1111/dom.12189. View

15.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

16.

Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl U . Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2014; 38(3):420-8. DOI: 10.2337/dc14-1096. View

17.

Yale J, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D . Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014; 16(10):1016-27. DOI: 10.1111/dom.12348. View

18.

Lavalle-Gonzalez F, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W . Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013; 56(12):2582-92. PMC: 3825495. DOI: 10.1007/s00125-013-3039-1. View

19.

Barnett A, Mithal A, Manassie J, Jones R, Rattunde H, Woerle H . Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014; 2(5):369-84. DOI: 10.1016/S2213-8587(13)70208-0. View

20.

Bailey C, Iqbal N, Tjoen C, List J . Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012; 14(10):951-9. DOI: 10.1111/j.1463-1326.2012.01659.x. View